Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 1;181(9):1241-1243.
doi: 10.1001/jamainternmed.2021.2209.

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette  1   2 , Olivier Hermine  3   4 , Pierre-Louis Tharaux  5 , Matthieu Resche-Rigon  6   7 , Philippe Gabriel Steg  8   9 , Raphaël Porcher  10 , Philippe Ravaud  10   11
Affiliations

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette et al. JAMA Intern Med. .

Abstract

This follow-up study of the CORIMUNO-TOCI-1 randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Steg reported personal fees from Amarin, Amgen, AstraZeneca, BMS, Idorsia, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier, and Regeneron as well as grants from Bayer, Sanofi, Servier, and Amarin outside the submitted work. Dr Ravaud reported being a minority shareholder of INATO outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Overall Survival Up to Day 90 in the CORIMUNO-TOCI-1 Trial
CRP indicates C-reactive protein.
See this image and copyright information in PMC

References

    1. RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. Preprint posted February 11, 2021. doi:10.1101/2021.02.11.21249258 - DOI
    1. Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi: 10.1056/NEJMoa2100433 - DOI - PMC - PubMed
    1. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed
    1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators . Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi: 10.1056/NEJMoa2028836 - DOI - PMC - PubMed
    1. Salvarani C, Dolci G, Massari M, et al. ; RCT-TCZ-COVID-19 Study Group . Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances